Report overview
This report contains market size and forecasts of Multivalent Vaccines in global, including the following market information:
Global Multivalent Vaccines Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Multivalent Vaccines Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Multivalent Vaccines companies in 2021 (%)
The global Multivalent Vaccines market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Conjugate Vaccines Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Multivalent Vaccines include GlaxoSmithKline, plc (U.K.), Pfizer, Inc (US), Merck & Co., Inc (US), Sanofi Pasteur SA (France), Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc (US), Johnson & Johnson (US) and MedImmune, LLC (US), etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Multivalent Vaccines manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Multivalent Vaccines Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Multivalent Vaccines Market Segment Percentages, by Type, 2021 (%)
Conjugate Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Recombinant Vaccines
Global Multivalent Vaccines Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Multivalent Vaccines Market Segment Percentages, by Application, 2021 (%)
Pediatrics
Adults
Global Multivalent Vaccines Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Multivalent Vaccines Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Multivalent Vaccines revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Multivalent Vaccines revenues share in global market, 2021 (%)
Key companies Multivalent Vaccines sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Multivalent Vaccines sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline, plc (U.K.)
Pfizer, Inc (US)
Merck & Co., Inc (US)
Sanofi Pasteur SA (France)
Astellas Pharma Inc. (Japan)
CSL Limited (Australia)
Emergent BioSolutions, Inc (US)
Johnson & Johnson (US)
MedImmune, LLC (US)
Serum Institute of India Pvt. Ltd. (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo (Japan)
Protein Sciences Corporation (US)
Panacea Biotec (India)
